On the occasion of World Cancer Research Day, the Spanish Association Against Cancer (AECC) highlights the need to move toward patient-centered research as a fundamental strategy to overcome oncology’s greatest challenge: achieving a 70% survival rate by 2030 and ensuring a better quality of life for people with cancer.
The Marqués de Valdecilla Research Institute (IDIVAL) joins this commitment through its seven cancer-specialized groups, which cover different dimensions of cancer and work in a coordinated manner across research areas such as: molecular pathology, cell cycle and stem cells, medical oncology, hematologic neoplasms and transplantation, translational hematopathology, cell signaling and therapeutic targets, as well as breast cancer and melatonin research—thus contributing to a patient-centered strategy.
In collaboration with Marqués de Valdecilla University Hospital and with national and international scientific networks, IDIVAL carries out multidisciplinary research aimed at ensuring that each advance translates into more lives saved.
Research that reaches the patient
IDIVAL’s mission is to bring science into the clinical setting to generate a real impact on patients’ lives. Its cancer units contribute to:
